Phase I Human Analytics (HALO) Study
Conditions
Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain InjurySummary
Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders.Additionally, the study aims to:* Evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis. * Evaluate data analysis techniques to improve risk stratification for participants through machine learning algorithms. * Direct participants to relevant and applicable clinical trials.
Detailed Description
Electronic medical records contain data that may indicate increased risk for certain diseases and disorders, but clinicians cannot easily discern the subtle patterns required to change their diagnostic and treatment patterns. This study seeks to use machine learning and data analysis techniques to increase diagnostic confidence and reduce time-to-diagnosis related to cardiovascular, oncologic, neurologic, and other diseases and disorders.
The study endeavors to develop ensemble multivariate biomarker risk scores to predict future development of diseases and disorders, improve diagnosis in preclinical states and increase diagnostic accuracy in the earliest clinical states. We also aim to evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis, improve risk stratification for participants through machine learning algorithms and direct participants to relevant and applicable clinical trials upon physician review, approval and recommendation.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Bernadette M. Greenwood, MSc
- 760-766-2047
Principal Investigator
- Christopher R. Hancock, MD
Eligibility Criteria
Inclusion Criteria:
Treatment Naïve patients:
* Male, 45 years of age or older.
* Diagnosis of prostate adenocarcinoma.
* Clinical stage T1c or T2a.
* Gleason score of 7 (3+4 or 4+3) or less.
* Three or fewer biopsy cores with prostate cancer.
* PSA density not exceeding 0.375.
* One, two, or three tumor suspicious regions identified on multiparametric MRI.
* Negative radiographic indication of extra-capsular extent.
* Karnofsky performance status of at least 70.
* Estimated survival of 5 years or greater, as determined by treating physician.
* Tolerance for anesthesia/sedation.
* Ability to give informed consent.
* At least 6 weeks since any previous prostate biopsy.
* MR-guided biopsy confirmation of one or more MRI-visible prostate lesion(s) with Gleason score of 7 (3+4 or 4+3) or less.
Salvage candidates will be accepted upon physician referral.
Exclusion Criteria:
* Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.
* Severe lower urinary tract symptoms as measured by an International Prostate Symptom Score (IPSS) of 20 or greater
* History of other primary non-skin malignancy within previous three years.
* Diabetes
* Smoker
Study Plan
dementia
Patients with a diagnosis of dementia
OTHER:
no interventions will be performed (observational)Description:
Not applicable. (no interventions will be performed with this observational study
Prostate cancer
patients with a diagnosis of prostate cancer
OTHER:
no interventions will be performed (observational)Description:
Not applicable. (no interventions will be performed with this observational study
breast cancer
Patients with a diagnosis of breast cancer
OTHER:
no interventions will be performed (observational)Description:
Not applicable. (no interventions will be performed with this observational study
Normal
Patients without a diagnosis
OTHER:
no interventions will be performed (observational)Description:
Not applicable. (no interventions will be performed with this observational study
tramatic brain injury
patients with a diagnosis of traumatic brain injury
OTHER:
no interventions will be performed (observational)Description:
Not applicable. (no interventions will be performed with this observational study
Outcome Measures
Primary Outcome Measures
Prostate cancer Gleason score
Prostate cancer ISUP grade group
Prostate cancer staging parameters
Prostate cancer specific mortality
Secondary Outcome Measures
Lower urinary tract symptoms (LUTS)
Erectile function
Emotional well-being
Incontinence level
PI-RADS category
Timeline
Last Updated
October 14, 2022Start Date
June 21, 2022Today
January 23, 2025Completion Date ( Estimated )
March 1, 2037
Sponsors of this trial
Lead Sponsor
HALO DiagnosticsCollaborating Sponsors
HALO Affiliate Sites